Bispecific Antibody Pretargeted Therapy of Pancreatic Cancer

双特异性抗体靶向治疗胰腺癌

基本信息

  • 批准号:
    7253359
  • 负责人:
  • 金额:
    $ 31.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-06-28 至 2009-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This project will examine the potential for improving radioimmunotherapy of pancreatic cancer using a bispecific antibody (bsMAb) pretargeting approach. We have previously shown very exciting data that pancreatic cancer specific anti-MUC1 MAb, PAM4, when radiolabeled with 90Y and combined with gemcitabine significantly enhanced the therapeutic effects of a gemcitabine regimen modeled after a human equivalent dosing regimen. We suspect that because pretargeting approaches can deliver similar amounts of radioactivity to tumors, but with less myelosuppression, that this type of procedure for targeting radionuclides would be preferred for eventual clinical use with gemcitabine. Therefore, one of the goals of this work will be to develop and test a bsMAb pretargeting procedure using PAM4 bsMAb with a 90Y or 177Lu- labeled peptide. AIM 1 includes studies designed to determine optimal targeting conditions for chemically conjugate F(ab')2 x Fab' or Fab' x Fab' PAM4 bsMAb. The optimal pretargeting conditions will be based on biodistribution and autoradiographic methods. Once optimized, the pretargeting procedures will be assessed for their therapeutic potential in the CaPanl cell line grown subcutaneously and orthotopically. Comparisons will be made between 90Y- and 177Lu as pretargeted agents, as well as to the directly radiolabeled PAM4 IgG. Repeat and fractionated doses will be examined. Combinational therapies will be tested using pretargeting added to a standard gemcitabine regimen, as well as assessing whether EGFR-based therapies (i.e., cetuximab and erlotinib) can further enhance this combination. Overall, these studies will assist in establishing whether this type of pretargeting approach could have a role in the clinical management of pancreatic cancer.
描述(由申请人提供):本项目将研究使用双特异性抗体(bsMAb)预靶向方法改善胰腺癌放射免疫治疗的潜力。我们之前已经显示了非常令人兴奋的数据,即胰腺癌特异性抗MUC 1 MAb,PAM 4,当用90 Y放射性标记并与吉西他滨组合时,显著增强了在人体等效给药方案后建模的吉西他滨方案的治疗效果。我们怀疑,由于预靶向方法可以向肿瘤提供相似量的放射性,但骨髓抑制较少,因此这种靶向放射性核素的方法将优选用于吉西他滨的最终临床应用。因此,本工作的目标之一将是开发和测试使用PAM 4 bsMAb与90 Y或177 Lu标记的肽的bsMAb预靶向程序。AIM 1包括设计用于确定化学缀合F(ab ')2 x Fab'或Fab' x Fab' PAM 4 bsMAb的最佳靶向条件的研究。最佳预靶向条件将基于生物分布和放射自显影方法。一旦优化,将评估预靶向程序在皮下和原位生长的CaPanl细胞系中的治疗潜力。将在作为预靶向剂的90 Y-和177 Lu之间以及与直接放射性标记的PAM 4 IgG之间进行比较。将检查重复给药和分次给药。将使用添加到标准吉西他滨方案中的预靶向来测试组合疗法,以及评估基于EGFR的疗法(即,西妥昔单抗和厄洛替尼)可以进一步增强这种组合。总的来说,这些研究将有助于确定这种类型的预靶向方法是否可以在胰腺癌的临床管理中发挥作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert M Sharkey其他文献

Robert M Sharkey的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert M Sharkey', 18)}}的其他基金

Biospecific Antibody Pretargeting for NHL
NHL 生物特异性抗体预靶向
  • 批准号:
    7728846
  • 财政年份:
    2008
  • 资助金额:
    $ 31.9万
  • 项目类别:
Molecular Engineering and Antibody Production
分子工程和抗体生产
  • 批准号:
    7728851
  • 财政年份:
    2008
  • 资助金额:
    $ 31.9万
  • 项目类别:
Dosimetry
剂量测定
  • 批准号:
    7728854
  • 财政年份:
    2008
  • 资助金额:
    $ 31.9万
  • 项目类别:
Bispecific Antibody Pretargeted Therapy of Pancreatic Cancer
双特异性抗体靶向治疗胰腺癌
  • 批准号:
    7091873
  • 财政年份:
    2006
  • 资助金额:
    $ 31.9万
  • 项目类别:
Bispecific Antibody Pretargeting for Therapy
双特异性抗体预靶向治疗
  • 批准号:
    7034913
  • 财政年份:
    2006
  • 资助金额:
    $ 31.9万
  • 项目类别:
Bispecific Antibody Pretargeting for Therapy
双特异性抗体预靶向治疗
  • 批准号:
    7389001
  • 财政年份:
    2006
  • 资助金额:
    $ 31.9万
  • 项目类别:
Bispecific Antibody Pretargeting for Therapy
双特异性抗体预靶向治疗
  • 批准号:
    7192578
  • 财政年份:
    2006
  • 资助金额:
    $ 31.9万
  • 项目类别:
Bispecific Antibody Pretargeting for Therapy
双特异性抗体预靶向治疗
  • 批准号:
    7572959
  • 财政年份:
    2006
  • 资助金额:
    $ 31.9万
  • 项目类别:
Bispecific Antibody Pretargeted Therapy of Pancreatic Cancer
双特异性抗体靶向治疗胰腺癌
  • 批准号:
    7414606
  • 财政年份:
    2006
  • 资助金额:
    $ 31.9万
  • 项目类别:
RAIT of Pancreatic Cancer with Humanized PAM4
人源化 PAM4 的胰腺癌 RAIT
  • 批准号:
    6682139
  • 财政年份:
    2003
  • 资助金额:
    $ 31.9万
  • 项目类别:

相似海外基金

Understanding age at first autism health claim and acute health service use in girls and women relative to boys and men
了解女孩和女性相对于男孩和男性的首次自闭症健康声明和紧急医疗服务使用情况
  • 批准号:
    419977
  • 财政年份:
    2020
  • 资助金额:
    $ 31.9万
  • 项目类别:
    Operating Grants
Proposal of a model plan for a high-activity operating department in an acute care hospital based on long-term PDCA in the age of minimally invasive treatment
微创治疗时代基于长期PDCA的急症医院高活动手术科室模型方案提出
  • 批准号:
    18K04486
  • 财政年份:
    2018
  • 资助金额:
    $ 31.9万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Study of pathogenic mechanism of age-dependent chromosome translocation in adult acute lymphoblastic leukemia
成人急性淋巴细胞白血病年龄依赖性染色体易位发病机制研究
  • 批准号:
    18K16103
  • 财政年份:
    2018
  • 资助金额:
    $ 31.9万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ISCHAEMIC ACUTE RENAL FAILURE AND AGE: MODULATION BY ANTI-INFLAMMATORY EMBRYONIC STEM CELL-DERIVED MACROPHAGES
缺血性急性肾衰竭和年龄:抗炎胚胎干细胞源性巨噬细胞的调节
  • 批准号:
    G0801235/1
  • 财政年份:
    2009
  • 资助金额:
    $ 31.9万
  • 项目类别:
    Research Grant
AGE-RELATED DIFFERENCES IN ENERGY EXPENDITURE IN RESPONSE TO ACUTE EXERCISE
剧烈运动时的能量消耗与年龄相关的差异
  • 批准号:
    7951393
  • 财政年份:
    2009
  • 资助金额:
    $ 31.9万
  • 项目类别:
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia
急性髓性白血病的年龄因素、突变和化学抑制剂
  • 批准号:
    8306217
  • 财政年份:
    2008
  • 资助金额:
    $ 31.9万
  • 项目类别:
Age-related differences in the acute thermoregulatory responses to cold
对寒冷的急性体温调节反应与年龄相关的差异
  • 批准号:
    347633-2008
  • 财政年份:
    2008
  • 资助金额:
    $ 31.9万
  • 项目类别:
    Postgraduate Scholarships - Master's
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia
急性髓性白血病的年龄因素、突变和化学抑制剂
  • 批准号:
    7530462
  • 财政年份:
    2008
  • 资助金额:
    $ 31.9万
  • 项目类别:
Acute and chronic GPCR Medicated Cardioprotection: Roles of receptor Cross-Talk, Cellular signaling, and effects of Age
急性和慢性 GPCR 药物心脏保护:受体串扰的作用、细胞信号传导以及年龄的影响
  • 批准号:
    nhmrc : 428251
  • 财政年份:
    2008
  • 资助金额:
    $ 31.9万
  • 项目类别:
    Career Development Fellowships
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia
急性髓性白血病的年龄因素、突变和化学抑制剂
  • 批准号:
    8134266
  • 财政年份:
    2008
  • 资助金额:
    $ 31.9万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了